Early Signals in FDA’s Direct-to-Consumer Drug Advertising Enforcement: Takeaways from Recent Letters
This Bulletin is brought to you by AHLA’s Life Sciences Practice Group.
- October 30, 2025
- Jae Kim , DLA Piper
- Stephanie Gumabon-Greaver , DLA Piper
- Christine Lentz , DLA Piper
Last month, the Food and Drug Administration (FDA) posted approximately 100 untitled letters and warning letters related to drug advertising and promotion. The number of letters starkly contrasts with the volume we have seen in previous years; for comparison, there were a total of five untitled letters and no warning letters issued in 2024.
ARTICLE TAGS
You must be logged in to access this content.